安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Deucravacitinib - Wikipedia
Deucravacitinib, sold under the brand name Sotyktu, is a medication used for the treatment of moderate-to-severe plaque psoriasis [7] It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth [7] It was developed by Bristol Myers Squibb [10]
- Deucravacitinib: Uses, Dosage, Side Effects Warnings - Drugs. com
Deucravacitinib (brand name Sotyktu) is a once-daily, oral tyrosine kinase 2 (TYK2) blocker that may be used to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy (light therapy)
- Deucravacitinib: A Complete Overview - DermNet
Deucravacitinib is a selective oral tyrosine kinase 2 (TYK2) inhibitor for the systemic treatment of moderate to severe plaque psoriasis and other immune-mediated diseases What is deucravacitinib used for?
- Deucravacitinib - StatPearls - NCBI Bookshelf
Deucravacitinib is a targeted treatment for patients with moderate-to-severe plaque psoriasis who qualify for systemic therapy or phototherapy This medication selectively inhibits the tyrosine kinase 2 (Tyk2) protein, providing greater efficacy and a superior safety profile compared to other biological agents, particularly apremilast
- SOTYKTU™ (deucravacitinib) Patient Site
SOTYKTU® (deucravacitinib) is an oral prescription medicine, TYK2 inhibitor, and once-daily pill used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills or treatment using ultraviolet (UV) light
- Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate . . .
Deucravacitinib is a novel oral TYK2 inhibitor that binds to the regulatory domain of TYK2, a Janus kinase By inhibiting TYK2, deucravacitinib interferes with signaling of IL-23, IL-12, and type I interferons, cytokines believed to play important roles in psoriasis pathogenesis
- Deucravacitinib (oral route) - Mayo Clinic
Deucravacitinib is used to treat moderate to severe plaque psoriasis, which is a skin disease with red patches and white scales that do not go away It is given to patients who may receive other types of treatment, including pills, injection, or phototherapy (light treatment)
- Deucravacitinib in plaque psoriasis: Four-year safety and efficacy . . .
Deucravacitinib demonstrated a consistent safety profile and durable efficacy through 4 years of treatment in patients with moderate to severe plaque psoriasis
|
|
|